MNPR — Monopar Therapeutics Inc. stock price, charts and financials

QT73Monopar Therapeutics Inc.

Monopar Therapeutics Inc. (NASDAQ: MNPR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
116.54
-2.67-2.24%
OverviewShort InterestFilings
MNPRQT73Monopar Therapeutics Inc.·NASDAQ
116.54-2.24%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.33%$15.48MESO+4.96%$16.73ZBIO-1.46%$31.96GHRS-2.07%$29.64TSHA-0.69%$6.51STOK-1.46%$32.23ABCL+31.03%$9.08VRDN-2.29%$23.05
Snapshot
Index-P/E-EPS (ttm)-Insider Own44.40%Shs Outstand6.70MPerf Week10.02%
Market Cap798.59MForward P/E-EPS next Y-3.48Insider Trans0.00%Shs Float4.16MPerf Month14.08%
Enterprise Value746.18MPEG2.04EPS next Q-Inst Own-Short Float32.67%Perf Quarter90.95%
Income-11.74MP/S0.00EPS this Y-Inst Trans-Short Ratio7.66Perf Half Y109.58%
Sales0.00P/B7.51EPS next Y-24.99%ROA-10.86%Short Interest1.36MPerf YTD82.56%
Book/sh-P/C-EPS next 5Y-ROE-12.84%52W High122.02 -4.49%Perf Year193.26%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-13.80%52W Low28.53 308.53%Perf 3Y3130.62%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility6.23% 7.16%Perf 5Y349.00%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-39.71%Oper. Margin0.00%ATR (14)7.45Perf 10Y-
Dividend Ex-Date-Quick Ratio56.04Sales Y/Y TTM-Profit Margin0.00%RSI (14)65.74Recom2.15
Dividend Gr. 3/5Y-Current Ratio56.04EPS Q/Q-21.05%SMA207.51%Beta1.43Target Price118.00
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA5032.31%Rel Volume1.02Prev Close119.21
Employees22LT Debt/Eq-EarningsAug 11SMA20065.91%Avg Volume218.09KPrice116.54
IPO DateDec 19, 2019Option/ShortNo / YesEPS/Sales Surpr.36.21% -Net Debt/EBITDA3.35Volume223,297Change-2.24%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-23-26ReiteratedUBS$105 → $125
Jul-22-26ReiteratedHC Wainwright & Co.Buy$105 → $125
Jun-30-26ReiteratedBTIGBuy$104 → $117
Jun-29-26ReiteratedUBS$37 → $105
Jun-02-26ReiteratedPiper SandlerOverweight$95 → $105
Jan-09-26InitiatedMorgan StanleyOverweight$115
Nov-14-25DowngradeRaymond JamesStrong Buy → Outperform$142 → $123
Oct-13-25InitiatedBarclaysOverweight$125
Oct-06-25ReiteratedRaymond JamesStrong Buy$80 → $142
Oct-02-25ReiteratedOppenheimerOutperform$115
Latest News
Jul-22-26
Jul-22-2611:59AM
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125Benzinga
08:00AM
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Diseaseglobenewswire.com
Jul-20-26
Jul-20-2608:00AM
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Teamglobenewswire.com
Jul-17-26
Jul-17-2603:58AM
Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy)SeekingAlpha
Jul-03-26
Jul-03-2610:10AM
Monopar Therapeutics: ALXN1840's Bull Case Has Improvedseekingalpha.com
Jun-30-26
Jun-30-2608:00AM
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Diseaseglobenewswire.com
Jun-26-26
Jun-26-2604:08PM
Monopar Therapeutics To Present New Analyses From Phase 3 FoCus Randomized Clinical Trial Of ALXN1840 At EAN 2026.Benzinga
Jun-23-26
Jun-23-2601:05PM
12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga
Company

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue
000——————
Cost of Goods Sold Incl. D&A
000——————
Gross Profit
000——————
Selling, General and Administrative Excl. Other6,80033——————
Research and Development9,904136——————
Other Operating Expense-16,68700——————
Operating Income-17-16-9——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)310——————
Net Income Before Taxes-14-16-8——————
Income Taxes
000——————
Consolidated Net Income-14-16-8——————
Net Income From Continuing Operations-14-16-8——————
Net Income-14-16-8——————
EPS (Recurring)-1.85-1.36-0.58——————
EPS (Basic, Before Extraordinaries)-1.85-1.36-0.58——————
EPS (Diluted)-1.85-1.36-0.58——————
EBITDA-14-16-8——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding71115——————
Market Capitalization45724226——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$133.74$104.42$75.11$45.80$16.48● Close Price0.00M8.75M17.50M26.25M35.00MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Robinson ChandlerChief Executive OfficerJun 30 '26Option Exercise0.0012,8730103,351Jul 02
Vu Quan AnhChief Financial OfficerJun 30 '26Option Exercise0.001,22802,728Jul 02
Cittadine AndrewChief Operating OfficerJun 30 '26Option Exercise0.005,254057,923Jul 02
Cittadine AndrewChief Operating OfficerMar 31 '26Option Exercise0.003,514054,240Apr 02
Robinson ChandlerChief Executive OfficerMar 31 '26Option Exercise0.006,732092,450Apr 02
Cittadine AndrewChief Operating OfficerDec 31 '25Option Exercise0.004,326052,615Jan 05
Robinson ChandlerChief Executive OfficerDec 31 '25Option Exercise0.008,724088,276Jan 05
Vu Quan AnhChief Financial OfficerDec 26 '25Buy69.951,500104,9251,500Dec 29
KLAUSNER ARTHUR JDirectorDec 18 '25Sale67.155,121343,8898,762Dec 19
Cittadine AndrewChief Operating OfficerSep 30 '25Option Exercise0.004,327050,185Oct 02
Robinson ChandlerChief Executive OfficerSep 30 '25Option Exercise0.008,726082,198Oct 02
Tactic Pharma LLC10% OwnerSep 24 '25Sale63.61550,22934,999,957272,026Sep 26
Tsuchimoto Kim RDirectorJul 14 '25Sale40.008,904356,17111,486Jul 16
Tsuchimoto Kim RDirectorJul 14 '25Option Exercise0.0113,6086920,390Jul 16
STARR CHRISTOPHER MDirectorJul 14 '25Option Exercise0.0116,8008421,973Jul 16
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.